HYBRID EVENT: You can participate in person at Tokyo, Japan or Virtually from your home or work.

International Heart Congress

May 24-25 | Hybrid Event

May 24 -25, 2023 | Tokyo, Japan
Heart Congress 2023

Clinical application in the prediction of 2 and 5-year clinical outcome of Polish patients with HCM

Agata Suleja, Speaker at Heart Conferences
Medical University of Silesia, Poland
Title : Clinical application in the prediction of 2 and 5-year clinical outcome of Polish patients with HCM


Introduction: Hypertrophic cardiomyopathy (HCM) is a genetic disease-causing variety of life-threatening complications. Atrial fibrillation (AF) in HCM population constitutes an important step in progression of the disease. Recently developed tool – HCM-AF Risk Calculator validated in American population allows accurate prognosis of AF occurrence in HCM patients.

Aim: To assess clinical application of HCM-AF Risk Score in the prediction of 2 and 5-year clinical outcome of Polish patients with HCM.

Materials and methods: The retrospective cohort study included 54 consecutive patients with HCM (52% female, median age 59) and baseline sinus rhythm diagnosed at the 1st Chair and Clinic of Cardiology, Medical University of Silesia in Katowice in 01.01.2013 - 31.12.2016. Analysis involved clinical characteristics, laboratory tests, echocardiography, Holter monitoring, 2- and 5-year clinical outcome (total mortality, re-hospitalization, ICD implantation, heart failure (HF) regarding the baseline HCM-AF Risk Score.

Results: According to HCM-Risk Score stratification 2 patients (3.7%) from analyzed cohort had low, 3 patients (5.6%) had intermediate, and 49 patients (90.1%) had high risk of AF. Both in low and intermediate-risk groups one patient developed AF, all patients survived, and no patients presented HF progression within 2-year and 5-year follow-up. Whereas in high-risk group AF has been detected in 24 (48.9%) patients within 2-year-follow-up and 31 (63.3%) patients within 5 year-follow-up, total mortality was 46.9% and HF progression was significant, and. Moreover, in explicitly distinguished subgroup of extremely high risk of AF (HCM AF Risk Score>45) 16 patients (84.2%) in 2-year-follow-up and 19 (100%) patients in 5 year-follow-up developed AF.

Conclusions: HCM-AF Risk Score seems to be useful in both prediction of AF occurrence and clinical outcome in HCM patients. Polish HCM population is characterized by relatively high HCM-Risk Score coexisting with high AF occurrence thus AF screening should be obligatory in this group.

Keywords: Hypertrophic Cardiomyopathy; Atrial Fibrillation; HCM-AF

Audience Takeaway:

  • Monitoring of HCM in Polish population
  • Progression and management of HCM in 2- and 5-year follow-up
  • Clinical application of novel risk assessment tools in HCM patients
  • Insight into further development of risk assessment tools for HCM patients


Mrs Agata Suleja is a 5th year medicine student at the Medical University of Silesia in Poland. Member of research group in Landesklinikum Wiener Neustadt. She has been awarded for variety of conference reports mostly in the field of cardiology but also bordering on radiology. She is an author of several research articles published in international journals. Awarded with “Best of the Best 2022” grant project of Polish Ministry of Education and with Rectors’ scholarship for the best student.